University of Pennsylvania
UPenn Biostatistics Working Papers
Year 

Paper 

Nested Markov Compliance Class Model in
the Presence of Time-Varying Noncompliance
Julia Y. Lin∗

Thomas R. TenHave†

Michael R. Elliott‡

∗
†
‡

This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the copyright holder.
http://biostats.bepress.com/upennbiostat/art11
Copyright c 2006 by the authors.

Nested Markov Compliance Class Model in
the Presence of Time-Varying Noncompliance
Julia Y. Lin, Thomas R. TenHave, and Michael R. Elliott

Abstract

We consider a Markov structure for partially unobserved time-varying compliance
classes in the Imbens-Rubin (1997) compliance model framework. The context is
a longitudinal randomized intervention study where subjects are randomized once
at baseline, outcomes and patient adherence are measured at multiple follow-ups,
and patient adherence to their randomized treatment could vary over time. We propose a nested latent compliance class model where we use time-invariant subjectspecific compliance principal strata to summarize longtudinal trends of subjectspecific time-varying compliance patterns. The principal strata are formed using
Markov models that related current compliance behavior to compliance history.
Treatment effects are estimated as intent-to -treat effects within the compliance
principal strata.
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SUMMARY
We consider a Markov structure for partially unobserved time-varying compliance
classes in the Imbens-Rubin (1997) compliance model framework. The context is
a longitudinal randomized intervention study where subjects are randomized once
at baseline, outcomes and patient adherence are measured at multiple followups, and patient adherence to their randomized treatment could vary over time.
We propose a nested latent compliance class model where we use time-invariant
subject-specific compliance principal strata to summarize longitudinal trends of
subject-specific time-varying compliance patterns. The principal strata are formed
using Markov models that related current compliance behavior to compliance history. Treatment effects are estimated as intent-to-treat effects within the compliance principal strata.
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Introduction

In randomized intervention studies where interventions are administered repeatedly, subject adherence to the randomized treatment may vary over time. We
consider a longitudinal compliance class model that uses nested principal stratification structure to characterize longitudinal compliance patterns over time within
which intent-to-treat effects are estimated. We consider a Markov structure for the
time-varying subject compliance behavior. We illustrate the model with analysis of the “Prevention of Suicide in Primary Care Elderly: Collaborative Trial”
(PROSPECT) study (Bruce et al. 2004).
The PROSPECT study was a randomized intervention study targeted at elderly
patients in primary care clinics with depression. There were two treatment groups:
usual care and the intervention. In the usual care group, patients received standard care. In the intervention group, patients were assigned to meet with health
specialists who educated patients, their families, and physicians about depression,
treatment, and monitored adherence to treatment. Primary care clinics were
randomized to the treatments rather than individual patients to prevent contamination of treatments between patients within the same clinic and for practicality.
Patients were followed for two years from the initial randomization. Clinical depression outcome and adherence to randomized treatment were measured at 4, 8,
12, 18, and 24 months. There were 598 patients in the study. The clinical outcome of interest is the severity of depression measured by the Hamilton Depression
Score (HAMD). The mean HAMD score at baseline is 18.1 with a standard deviation of 6.0. We consider an all-or-none treatment adherence measured by whether
patients met with the health specialists at least once since the previous followup period. We are interested in investigating the effect of the intervention on
depression severity controlling for treatment non-adherence.
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In randomized intervention studies where subjects do not always adhere to the
treatment to which they are randomized, subject noncompliance could confound
the relationship between the treatment and the outcome. Therefore, it is important to account for subject noncompliance when estimating the effect of the
treatment using principal stratification strategies (Frangakis and Rubin, 1999,
2002). Angrist et al. (1996) and Imbens and Rubin (1997) proposed to use
compliance classes to describe subject compliance behaviors within which intentto-treat (ITT) contrasts are made to estimate the causal effect of the treatment
on the outcome.
In cross-sectional studies with two treatment arms, experimental treatment and
control treatment, there are four possible compliance classes: compliers, alwaystakers, never-takers, and defiers. Compliers are those that would adhere to the
treatment to which they are assigned; always-takers are those that would seek
to receive the experimental treatment regardless of their treatment assignment;
never-takers are those that would opt to receive the control treatment regardless of
their treatment assignment; and defiers are those that would refuse the treatment
to which they are assigned and choose to receive the other treatment. In this
study design, subject compliance classes are latent. An individual assigned to
the experimental treatment and receives the experimental treatment could be a
complier or an always-taker; an individual assigned to the experimental treatment
but receives the control treatment could be a never-taker or a defier; an individual
assigned to the control treatment and receives the control treatment could be a
complier or a never-taker; and an individual assigned to the control treatment but
receives the experimental treatment could be an always-taker or a defier.
In studies, such as PROSPECT, where those assigned to the control treatment
have no access to the experimental treatment, there are only compliers and nevertakers. Always-takers do not exist in such study designs because those randomized
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to the control treatment cannot receive the experimental treatment, and defiers
do not exist for the same reason. The compliance classes for those assigned to
the experimental treatment in this study design are observed. Subjects assigned
to and receive the experimental treatment are compliers; subjects assigned to the
experimental treatment but choose to receive the control treatment are nevertakers. The compliance classes for those assigned to the control treatment are
unobserved.
In this paper we propose an extension of the cross-sectional model in Imbens
and Rubin (1997) to longitudinal settings. Yau and Little (2001) extended the
Imbens and Rubin (1997) model to a longitudinal randomized intervention study
where unemployed subjects received preventive intervention and their employment
and mental health outcomes were measured. Although outcomes were measured
repeatedly over time, the intervention was only administered once in the beginning
of the study. Therefore, adherence to intervention was only recorded once and did
not vary over time. Our proposed model allows treatment adherence to vary over
time.
In longitudinal randomized intervention studies where treatments are applied repeatedly, subject treatment adherence could vary over time. In Frangakis et al.
(2004), the randomized distance between the needle exchange truck and subjects’
residence could change over time, and subject needle exchange behavior could also
vary over time. HIV (human immunodeficiency virus) seroconversion status were
recorded at multiple follow-ups. The goal of the analysis was to determine the
effect of exchanging needles on HIV seroconversion, taking into account the history of compliance behaviors. This model differs from our proposed model in two
ways: 1) we do not allow randomization status to change over time; 2) we propose
a nested model structure that uses subject-specific time-invariant principal strata
to summarize subject-specific time-varying compliance behavior.
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In the presence of time-varying compliance behaviors, it may be useful to consider
longitudinal compliance behavior patterns when examining longitudinal outcomes.
Subjects with different compliance trajectories may differ in treatment outcomes.
We may make inferences on different longitudinal compliance patterns and the
longitudinal outcomes associated with those patterns. In a study like PROSPECT
where there are two possible compliance classes and 5 follow-up visits, we have
32 (25 ) possible compliance patterns. It may be impractical and not clinically
meaningful to look at the longitudinal outcomes in all of the 32 patterns. Hence,
it may be more helpful to have summary measures of the longitudinal compliance
patterns in the data, and look at longitudinal outcomes within broader latent
classes.
This paper extends a nested latent class model proposed by Lin et al. (in preparation) to accommodate time-varying latent compliance classes by specifying broader
principal strata that summarize the compliance classes. The nested latent class
model involves two levels of compliance class models. The first level uses subjectspecific time-varying compliance classes to describe the time-varying treatment
adherence; the second level uses subject-specific time-invariant compliance “superclasses” to summarize the longitudinal patterns of compliance classes. The ITT
effect of the intervention stratified on compliance superclass, or principal effect
(Frangakis and Rubin 2002), is estimated to control for longitudinal subject treatment noncompliance. The model assumes that compliance classes at each time
point within an individual are independent from each other conditional on the
individual’s compliance superclass and baseline covariates. In other words, knowing the compliance superclass and subject baseline characteristics, the history of
compliance behaviors does not provide any more information on the compliance
behaviors. This may be a strong assumption which we now propose to assess with
a Markov model for the time-varying compliance classes.
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Collins and Wugalter (1992) first proposed latent transitional models to model
dynamic latent classes where subjects advance through a sequence of latent stages
and to look at the relationship between the latent stages. The model estimates
the probabilities of remaining in the same stage or advancing to the next stage
conditional on previous stage. This method was applied to the process of math
learning (Collins and Wugalter, 1992) and stages of smoking cessation (Velicer
et al., 1996). Extensions by Reboussin et al. (1999), Humphreys and Janson
(2000), and Reboussin et al. (2002) incorporated covariates to estimate the latent
transitional probabilities using logistic regression. This latent transitional model
was also extended to accommodate multiple indicators for estimating latent stages
(Reboussin et al., 1998) and mixed outcomes (Miglioretti, 2003).
Markov transition models have been used to study cost effectiveness of depression
treatments in treating patients with major depression (Nuijten et al., 1995; Revicki
et al., 1995). In behavioral health studies where treatments may be dynamic, it
may be important to consider previous treatment adherence to better characterize
course of treatment. Previous adherence to treatments may provide insights on
how patients would respond to treatments in the future.
In this paper, we extend the longitudinal nested compliance class model in Lin
et al. (in preparation) and relax the conditional independence assumption of
the compliance classes given compliance superclass and baseline covariates. We
assume a first-order Markov structure for the compliance classes given superclass
and baseline covariates where compliance behaviors are assumed to depend on the
compliance class in the previous time point. Modelling the Markov structure of
the time-varying compliance classes will allow us to: 1) utilize information from
history of compliance to predict compliance behaviors; 2) examine how history of
compliance relate to compliance behavior.
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We will define notation, discuss assumptions, principal effect, the parametric
model, parameter estimation, the handling of missing outcomes, and assessment
of model fit in Section 2. Then we will proceed to discuss the analysis results in
Section 3, and finally make concluding remarks in Section 4.

2
2.1

Nested Compliance Class Model
Notation

Let Zi denote the randomization status for subject i where i = (1, · · · , N ), and
Zi ∈ (0, 1) for randomized to the usual care and the intervention group, respectively. Similarly, let Dij denote the time-varying treatment received for subject i
at time j where j = (1, 2, 3, 4, 5) for 4, 8, 12, 18, and 24 months, respectively, and
Dij ∈ (0, 1) for usual care and intervention, respectively. Note that Zi does not
have the subscript j because we are restricting to designs where randomization
does not change over time. Let Yij denote the observed outcome for subject i at
time j. We use Z, D, Y to denote vectors of Zi , Dij , and Yij .
Following Little and Rubin (2000), we use Yij (Z) to denote the partially latent
potential outcome, outcome that would have been observed, for subject i at time
j if randomized to treatment Z. Let Cij denote membership of the partially
latent compliance classes for subject i at time j. In the PROSPECT study, since
those randomized to the usual care group have no access to the intervention, there
are only two possible compliance classes: compliers and never-takers; therefore,
Cij = (c, n). We use C to denote the vector of Cij .
The proposed principal stratification strategy uses compliance “superclasses” to
summarize the longitudinal compliance patterns in the data within which we can
stratify on and compare potential outcomes. It precludes the confounding when
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stratifying on observed post-randomization compliance patterns. Let Ui denote
membership of the latent superclass for subject i, where Ui = (1, · · · , K) for
assumed K numbers of latent superclasses. We use U to denote the vector of Ui .
Subject-level baseline covariates Ai and Qi are used in modelling the outcome
and compliance probabilities, respectively. We use A and Q to denote the vector
of Ai and Qi .
We use upper case letter to denote random variables or indices of potential outcomes (e.g. Yij (Z)), and lower case letter to denote realized or observed values of
the random variables or indices (e.g. Zi = z).

2.2

Assumptions

We make the randomization (Rubin, 1978), stable unit-treatment value (SUTVA;
Rubin, 1986), and model assumptions to identify causal model parameters. We
assume that potential outcomes, latent compliance classes, and latent compliance superclasses (which are assumed to be baseline characteristics) are independent of randomization assignment status conditional on baseline covariates. We
make the no interference assumption of the SUTVA and assume that the potential outcome of an individual is not influenced by the treatment assignment
of another individual. We also make the consistency assumption of the SUTVA
which assumes that the potential outcome of a certain treatment will be the
same regardless of the treatment assignment mechanism. It implies that the observed outcome is a function of the potential outcomes and treatment assignment:
Yij = Zi ∗ Yij (1) + (1 − Zi ) ∗ Yij (0). The SUTVA assumption is violated when
there are interference between subjects or when there are versions of treatments
not represented by the treatment indicator variable.
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Principal Effects

We utilize compliance superclasses to summarize the longitudinal compliance patterns, and estimate ITT effects stratified on these superclasses. A compliance
superclass is a latent subject-level principal stratum that is time-invariant, and
is considered to be a pre-randomization characteristic which would allow us to
model potential outcomes.
Our effect of interest is the principal effect of treatment assignment on the outcome
within a compliance superclass at time j:

E[Yij (1)|Ui = k] − E[Yij (0)|Ui = k]

(1)

It is an ITT contrast stratified on the compliance superclass. It allows us to
consider the effect of treatment randomization controlling for longitudinal compliance behavior. Since the superclasses defined here create baseline principal
strata summarizing longitudinal compliance behaviors and do not represent specific longitudinal compliance patterns, the ITT contrasts sacrifice straightforward
causal interpretations.
The principal effect can be defined by observed outcomes under the randomization
and the SUTVA consistency assumption:

E[Yij (Z = 1)|Ui = k] − E[Yij (Z = 0)|Ui = k]
= E[Yij (Z = 1)|Zi = 1, Ui = k] − E[Yij (Z = 0)|Zi = 0, Ui = k]

(2)

= E[Yij |Zi = 1, Ui = k] − E[Yij |Zi = 0, Ui = k]

The first equal sign follows from the randomization assumption, which says that
randomization is independent of baseline characteristics (e.g. potential outcomes)
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conditional on baseline covariates (e.g. compliance superclass). The second equal
sign follows from the SUTVA consistency assumption which implies that the observed outcome given treatment assignment z is the potential outcome for treatment assignment Z = z.

2.4

Parametric Model

Lin et al. (in preparation) proposed a conditional independence (CI) model where
longitudinal compliance classes within an individual were assumed to be independent given compliance superclass and baseline covariates. Under the current
proposed method we relax the CI assumption. We assume compliance classes are
dependent on the compliance classes at one or more previous time points, the
compliance superclass, and baseline covariates.
Following Lin et al. (in preparation), we assume outcomes within individuals are
independent given randomization, time-varying compliance class, baseline covariates, and subject-level random effect.
¡

¢
2
Yij |Ci1 , · · · , Cij , Zi = z, Ai , Wi , λ, ζ(t, j), γ, ϕi , σ 2 ind
∼ N (µijz , σ )
"
#
j
X
X
µijz =
I(Cit = η 0 , Zi = z)λtη0 z ζ(t, j) + ATi γ + WiT ϕi
t=1

(3)

η0

where λ denotes the vector of λtη0 z parameters for t ≤ j that describe the
compliance-class specific ITT effect of the treatment on the outcome, and ζ(t, j)
modifies that ITT effect at time t on the outcome at time j that we will discuss more later. The conditional mean of the outcome has three components:
compliance class-specific effect of randomization, the effect of baseline covariates,
and the subject-specific random effects to account for within-subject correlation
in the outcomes. The compliance class-specific effect of randomization on out-
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0
0
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η
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Z
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z)λ
ζ(t,
j)
. The effect of
it
i
tη z
η0

the baseline covariates on the outcome is represented by ATi γ where Ai denotes
the vector of baseline covariates of subject i, and the column vector γ denotes the
corresponding coefficients. The random effects ϕi is used to account for withinsubject correlation in the outcomes, where Wi denotes the random effect design
matrix for subject i. Previous analysis indicated that the within-clinic correlation
was small (0.075), hence was ignored in this analysis. In this paper, we consider
a random subject-level intercept model.
In some studies, it may be reasonable to consider decay of treatment effects over
time. For example, the concentration of drugs in the body diminishes over time
and may not completely dissipate before the next administration. Therefore, it
would be important to model the decay of effect of the previous treatment when
estimating the effect of the treatment. In the PROSPECT study we may consider
the decay of the effect of previous compliance behavior on the outcome. It is
conceivable that information ascertained in meetings with health specialists may
have lasting effects on the subjects and their treatment outcomes. We can use the
parameter ζ(t, j) to modify the relationship between compliance behavior at time
t on the outcome at time j. We can assume a transient relationship where the
outcome is only dependent on the current compliance behavior (i.e. ζ(t, j) = I(t =
j)); assume a non-transient relationship where ITT effect is dependent on current
and all prior compliance behavior (i.e. ζ(t, j) = I(t ≤ j)); or assume a decaying
relationship where the outcome is dependent on current and all prior compliance
behavior, but the effect diminishes as time lag increases (i.e. ζ(t, j) = e−τ (j−t)
where τ > 0). Preliminary analysis of the data using a decay model suggested
τ → ∞, or a transient relationship between compliance behavior and ITT effect.
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Hence, we consider the transient model:

µijz =

X

[I(Cij = η 0 , Zi = z)λjη0 z ] + ATi γ + WiT ϕi

(4)

η0

Departing from Lin et al. (in preparation), we propose a Markov compliance
class (MCC) model for the time-varying compliance classes, where the compliance classes are dependent on past compliance behavior. Following Lin et al.
(in preparation), we assume that compliance superclass is an underlying factor that drives subject compliance over time. We model compliance class at
the first time point conditional on compliance superclass and baseline covariates Qi using logit models: P (Ci1 = η|Ui = k, Qi ) = ωkη (Qi ) and ωkη (Qi ) =
P
P
exp(α0kη + α1η Qi )/[ η0 exp(α0kη0 + α1η0 Qi )] where η ωkη (Qi ) = 1 ∀k. We constrain α0kη and α1η for one of the compliance class η to be 0 for identifiability.
We assume subject compliance superclass (Ui = k) ∼ M ultinomial(1, pk ), where
P
k pk = 1. Compliance superclass between subjects are assumed to be indepenQ
dent: f (U) = N
i=1 f (Ui = k) for k = 1, · · · , K where f (.) denotes the distribution
function.
We utilize latent transitional models (Collins and Wugalter, 1992) to model the
Markov process of compliance classes across time. In this paper we consider
a non-stationary first-order Markov compliance model. The number of model
parameters in multiple-order Markov models increase exponentially without additional constraints such as stationarity. Because of the lack of good predictors of compliance transitions, we assume that there are no associated covariates.
al.

Covariates can be incorporated using logit models as in Reboussin et
(1999) and Humphreys and Janson (2000).

We assume the compliance

class transitions (Cij = η|Ci,j−1 = η 0 , Ui = k) ∼ M ultinomial(1, πkjη0 η ), where
P
0
η πkjη 0 η = 1 ∀k, j, η . The joint distribution of the compliance classes given
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compliance superclass then becomes:

P (Ci1 , · · · , Ci5 |Ui , Qi ) = P (Ci1 |Ui , Qi )P (Ci2 |Ci1 , Ui ) · · · P (Ci5 |Ci4 , Ui )

(5)

If the compliance class and compliance superclass memberships, and the missing
outcomes are known, the joint distribution of the complete data for subject i given
the model specifications is as follows:
f (Yi1 , · · · , Yi5 , ϕi , Ci1 , · · · , Ci5 , Ui |Zi , Ai , Qi , Wi , θ)
= f (Yi1 , · · · , Yi5 |ϕi , Ci1 , · · · , Ci5 , Ui , Zi , Ai , Qi , Wi , θ) ×
f (ϕi |Ci1 , · · · , Ci5 , Ui , Zi , Ai , Qi , Wi , θ) ×
f (Ci1 , · · · , Ci5 |Ui , Zi , Ai , Qi , Wi , θ)f (Ui |Zi , Ai , Qi , Wi , θ)

(6)

= f (Yi1 , · · · , Yi5 |Ci1 , · · · , Ci5 , Zi , Ai , Wi , λ, γ, ϕi , σ 2 ) ×
f (ϕi |Σϕ )f (Ci1 , · · · , Ci5 |Ui , Qi )f (Ui )
where θ = (λ, γ, σ 2 , Σϕ )

2.5

Estimation

We use a Bayesian Markov Chain Monte Carlo (MCMC) method to estimate
model parameters. Let β = [λ1c0 , · · · , λ5n1 , γ]T denote the fixed effects. We assume the conjugate priors β ∼ M V N (µβ , Σβ ) and σ 2 ∼ Inv − χ2 (df = νσ , ψ). We
assume ϕi ∼ M V N (0, Σϕ ) for the subject-level random effects, and the hyperprior Σϕ ∼ Inv −W ishart(df = νϕ , Γ). For compliance superclass and compliance
class probabilities, we assume the priors (p1 , · · · , pK ) ∼ Dirichlet(a1 , · · · , aK ),
α ∼ M V N (0, Σα ), and (πkjη0 c , πkjη0 n ) ∼ Dirichlet(bc , bn ) ∀k, j, η 0 . Gibbs sampling (Geman and Geman, 1984; Gelfand and Smith, 1990; Imbens and Rubin,
1997; Gelman et al., 2004) is used to otbain draws from the posterior distributions
of the parameters. The posterior distributions from which the model parameters
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are drawn are presented in the Appendix. The posterior distribution (α|C, U, Q)
where α = [α01c , · · · , α0Kn α1c , α1n ] is not of a known parametric form. Therefore,
we use the Metropolis-Hasting algorithm (Hastings, 1970, Gelman et al., 2004) to
draw the α parameters.

2.6

Missing Outcome Imputation

There are missing outcomes (Yij ) present in the PROSPECT data. We assume a
latent ignorable missing data mechanism (LIMD; Peng et al., 2004) for the missing
outcomes, which assumes missing at random given latent compliance class and
covariates. At each iteration of the MCMC procedure, we impute the missing
outcomes conditional on compliance classes, treatment randomization, baseline
covariates, and subject-level random effects. We draw missing outcome Yijmis
for subject i at time j from its predictive distribution given current values of
parameters Cij , λjηz , γ, ϕi , σ 2 , and vector of observed outcomes Yobs .
(Yijmis |Yobs , Cij , Zi = z, Ai , Wi , λjηz , γ, ϕi , σ 2 ) ∼ N (µ∗ijz , σ 2 )
X
µ∗ijz =
[I(Cij = η 0 , Zi = z)λjη0 z ] + ATi γ + WiT ϕi

(7)

η0

2.7

Model Fit Assessment

We compare the fits of the MCC model to the CI model in Lin et al. (in preparation) by comparing the posterior predictive distributions (PPD; Gelman et al.,
2004) of the time-varying compliance classes between the MCC and the CI models.
Let Gm denote the number of individuals in the mth of the 32 possible longitudinal
compliance patterns and let κm be the estimated probability of exhibiting the mth

http://biostats.bepress.com/upennbiostat/art11

7/5/06

14

longitudinal compliance pattern. We consider the χ2 -type statistics:
S obs =

X (Gobs − N κm )2
m

m

N κm (1 − κm )

and S rep =

X (Grep − N κm )2
m

m

N κm (1 − κm )

(8)

rep
where Gobs
m is the observed statistics and Gm is the repeated statistic obtained

from draws of the parameters generated by the Gibbs sampler. The PPD p-value
is then given by:
P
l

I[(S obs )l < (S rep )l ]
P
l1

(9)

where (S obs )l and (S rep )l denote the S obs and S rep from lth Gibbs draw. A PPD
p-value close to 0.50 indicates good fit of the model to the data.

3

Results

We demonstrate the MCC model with the PROSPECT data and compare the
results to the CI model assuming three superclasses. There are unrecorded treatment received (Dij ) in the data, of which we assume are 0, or have not met with
health specialists. Imputation of missing outcomes is as described in Section 2.6.
In the PROSPECT study, those randomized to the usual care group do not have
access to the intervention; therefore, there are only two compliance classes: compliers and never-takers. Goodman (1974) suggests that we can only identify at
most 3 latent compliance superclass given 5 dichotomous compliance classes. Lin
et al. (in preparation) showed that the 3-superclass CI model fits the data better
than the 2-superclass CI Model. Our effect of interest is the effect of the health
specialists on the severity of depression. More specifically, we are interested in the
principal ITT effect of the intervention on the outcome stratified on compliance
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superclass.

E[Yij (Z = 1)|Ui = k] − E[Yij (Z = 0)|Ui = k]
X
=
(λjη0 1 − λjη0 0 ) P (Cij = η 0 |Ui = k)

(10)

η0

In this analysis we let Ai be the baseline HAMD score and baseline suicidal
ideation. We want to control for the baseline HAMD because we are interested
in the change in HAMD scores from baseline. Treatment randomization failed to
balance the proportion of subjects with baseline suicidal ideation in the treatment
groups; therefore, we want to control for it in modelling the outcome. We let Qi
be the baseline HAMD score in estimating the compliance probabilities in the CI
model and in estimating the initial compliance probabilities in the MCC model.
We use noninformative priors in the Bayesian MCMC estimation of the model
parameters since we do not have strong prior inclinations. Following Garrett
and Zeger (2000) and Ten Have et al. (2004) we assume α ∼ M V N (0, Σα =
diag(50, 4)). The difference in variance component in the priors reflect the different scaling of the covariates. A larger variance is used for binary covariates (i.e.
intercept) and a smaller variance is used for continuous covariates (i.e. baseline
HAMD score; Garrett and Zeger, 2000, Ten Have et al., 2004). The identifiability of the α parameters are checked by comparing the prior and the posterior
distributions (Garrett and Zeger, 2000). We assume the prior (πkjη0 c , πkjη0 n ) ∼
Dirichlet(0.01, 0.01)∀k, j, η 0 for the transitional probabilities. This is equivalent to
adding 0.01 subject to each of the (Ci,j−1 = η 0 , Cij = η|Ui = k) groups. We assume
β ∼ M V N (µβ = 0, Σβ = 1000 × I) and σ 2 ∼ Inv − χ2 (νσ = 1, ψ = 1/10). For the
random effect variance parameter we assume Σϕ ∼ Inv − χ2 (νϕ = 1, Γ = 1/10).
We assume the prior (p1 , · · · , pK ) ∼ Dirichlet(1, · · · , 1), assigning a priori 1 subject to each of the K superclasses.
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We used the Gelman-Rubin R̂ statistic (Gelman et al., 2004, pp.296-297) to assess
the convergence of the MCMC chains and R̂ < 1.1 is accepted as evidence of
convergence. We ran 3 chains of the CI model for 10,000 iterations each and the
first 1,000 iterations was discarded as burn-in, and we ran 3 chains of the MCC
model for 150,000 iterations each and the first 75,000 iterations was discarded as
burn-in. The maximum R̂ was 1.05 and 1.08 for the CI and the MCC models,
respectively.
We will present the results under the CI model as specified in Lin et al. (in
preparation), then the results under the MCC model, follow by comparison of the
two models. We can assess the conditional independence assumption made under
the CI model by comparing the fit of the CI model to the fit of the MCC model
to the data. We also compare the results under different model assumptions for
the time-varying compliance classes.

3.1

Conditional Independence Model

For comparison, results under the CI model as described in Lin et al. (in preparation) are displayed in Tables 1 and 2. Table 1 shows the time- and superclassvarying compliance probabilities from the CI model assuming the average baseline
HAMD of 18.1, and table 2 shows the ITT effect of randomization on the outcome within each compliance superclass controlling for the baseline HAMD and
baseline suicidal ideation.
Table 1 shows that the first superclass under the CI model consists of subjects who
are noncompliant at the 4-month follow=up and become even more noncompliant
for the remainder of the study (low compliers). The second superclass consists
of subjects who are highly compliant for the first 3 months and rapidly become
noncompliant (decreasing compliers). The third superclass consists of subjects

Hosted by The Berkeley Electronic Press

7/5/06

17

who are highly compliant but become slightly less compliant at the last follow-up
visit (high compliers). About 28% of the subjects in the PROSPECT study are
low compliers with 95% credible interval (0.23,0.33), 16%(0.12,0.22) are decreasing
compliers, and 56%(0.50,0.62) are high compliers.

[Table 1 about here.]

The posterior mean and the 95% credible interval of the log odds of compliance for
every unit increase in baseline HAMD is 0.003(-0.04,0.05) suggesting those with
more severe depression at baseline (higher baseline HAMD) are more likely to
comply to treatment assignment than those with less severe depression at baseline.
The within-superclass ITT contrasts of (10) are shown Table 2. The contrasts
suggest strong direct effect of randomization at the 4-month follow-up in the low
complier superclass, which consists of largely never-takers, who are unlikely to
meet with health specialists regardless of the treatment assigned. The direct
effect of randomization on the outcome could be due to the unblinded nature of
the intervention. The presence of the health specialists in the clinics may influence
the behaviors of the health care providers and patients. The possible direct effect
of randomization seems to dissipate over time. At the end of the first year, only
the high compliers randomized to the intervention group, who are still highly
likely to meet with a health specialist when assigned to the intervention, showed
greater reduction in HAMD relative to high compliers in usual care. At the end of
the 2-year study, none of the superclasses show strong ITT effects on depression.

[Table 2 about here.]
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Markov Compliance Class Model

The Markov compliance class model relaxes the conditional independence assumption of the time-varying compliance class given compliance superclass and
baseline covariates, and instead, assumes a first-order Markov structure for the
time-varying compliance classes given compliance superclass. Again, we assume
3 compliance superclasses.
The posterior means of the log odds of compliance at 4 months and their associated 95% credible intervals within each of the three superclasses controlling for
baseline HAMD under the MCC model are -0.52(-1.87,0.81), -3.61(-15.56,4.37),
and 4.99(1.11,13.69) for the first, second, and third superclass, respectively. This
suggests that at the 4-month follow-up, those in the first and second superclasses
are less likely to comply with their treatment assignment, and those in the third
superclass are more likely to comply with their treatment assignment. In our
model we assume that the association between baseline HAMD and compliance
probability at 4 month is the same across all three superclasses. The log odds of
4 month compliance for a unit increase in the baseline HAMD is 0.07(0.01,0.13)
suggesting that those with more severe depression at baseline are more likely to
comply with treatment assignment.
Table 3 shows the time-varying compliance probabilities when we assume an average baseline HAMD score of 18.1. The first superclass consists of subjects who are
slightly more likely to comply with assigned treatment at the 4-month follow-up
than not comply, and compliance decreases over time (increasing noncompliers).
The second superclass consists of subjects who exhibit erratic compliance behavior
with abrupt increases and decreases in compliance probabilities (erratic compliers). The third superclass consists of subjects who are highly compliant during
the first 18 months of the study with a slight drop off in compliance during the
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last 6 months (high compliers). The mean posterior probabilities and their associated 95% credible intervals of membership in the increasing noncomplier, erratic
complier, and high complier superclasses are 0.42(0.25,0.56), 0.04(0.00,0.15), and
0.54(0.42,0.72), respectively.

[Table 3 about here.]

The latent transitional probabilities of the time-varying compliance within each
superclass in Tables 4 shows that increasing noncompliers and high compliers are
more likely to stay in the complier class if they are in the complier class in the
previous time point than if they are in the never-taker class and switch to complier
class. Subjects in the high complier superclass are more likely to transition to the
complier class than subjects in the increasing noncomplier superclass. We do not
see any clear patterns in the transitional probabilities of the erratic compliers.

[Table 4 about here.]

The posterior means and credible intervals of (10), the within-compliance superclass ITT contrasts, in Table 5 show an ITT effect at 4 months in the erratic
compliers, suggesting a strong direct effect of randomization. The erratic complier superclass consists of mostly never-takers at 4 months, who are unlikely to
meet with health specialists if assigned to the intervention. This direct effects
seems to dissipate over time. We also see an ITT effect in the high compliers at
4 months, suggesting an effect of the intervention. The high complier superclass
consists of almost entirely compliers at 4 months, who are likely to meet with
health specialists if assigned to the intervention. Consistent with the results under the CI model, at the end of the first year we see a greater reduction in HAMD
in the high compliers assigned to the intervention relative to the high compliers
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assigned to the usual care. It suggests that meeting health specialists help improve depression. However none of the superclasses show strong ITT effects on
depression.

[Table 5 about here.]

3.3

Model Comparison

In this section we compare the superclasses identified under the CI and the MCC
compliance class structures. Under both compliance class structures we identified
a superclass of high compliers, who are highly compliant throughout the study
period with slight decrease in time-varying compliance at the last follow-up visit.
We also identified a superclass that exhibits decreasing time-varying compliance;
however, the compliance probability under the CI model starts out much higher
at 4 months and decreases at a faster rate over subsequent visits than the compliance probability under the MCC model. Under the CI model we identified a
superclass of subject who are noncompliant, with no clear time trend in their compliance probabilities. Under the MCC model we identified a superclass of subjects
exhibiting erratic compliance behavior with fluctuating compliance probabilities
and no clear trend in their compliance class transitions.
We saw similar within-compliance superclass ITT effects under both the CI and
the MCC models. The ITT effects were larger in noncompliant subjects than
compliant subjects at the 4-month follow-up suggesting a direct effect of randomization early on. This is most evident in the low complier superclass under the CI
model and the erratic complier superclass under the MCC model, both of which
consist of mostly never-takers at 4 months, who exhibit the largest ITT effects.
However, this direct effect seems to dissipate over time. At the 24-month follow-
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up we see the largest ITT effect in the high complier superclass under both the
CI and the MCC models, which consist of mostly compliers. Although none of
the ITT effects were strong in any of the superclasses under both models by the
end of the study.
Assessment of the fit of the posterior predictive distribution to the data using the
χ2 -type statistics in (8) suggests that the MCC model has a better fit than the
CI model. The PPD p-value under the CI model is 0.0057 and 0.1549 under the
MCC model.

4

Discussion

In Lin et al. (in preparation), a conditional independence model of the timevarying compliance classes was proposed that assumes the compliance classes
within an individual are independent given compliance superclass and baseline
covariates. People are creatures of habit. Those that exhibit history of compliance to an assigned treatment may be more likely to comply than those that
exhibit history of noncompliance. In this paper, we proposed a Markov model
of the time-varying compliance classes that assumes the compliance classes at
each time point are dependent on the previous compliance behaviors, compliance
superclass, and baseline covariates.
Under the MCC model we found that those who are more depressed at baseline
are more likely to comply with their treatment assignment at 4 months. The
same trend was also found under the CI model. Patients who are more depressed
may be more eager to treat their depression and be more likely to adhere to their
prescribed treatment. Physicians may also monitor patients with more severe
depression more closely, making sure that the patients adhere to their treatments.
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The proposed MCC model provides information on how treatment compliance
relates to history of compliance that was not considered in the CI model. We
found that most of the subjects in the PROSPECT study who complied to the
treatment assignment in the previous follow-up period were more likely to comply
again than those who were noncompliant during the previous visit.
When we compared the posterior predictive distributions under the MCC and the
CI models to the data, we found that the MCC model fit the data much better
than the CI model. The MCC model is a more flexible model; therefore, we expect
it to have a better fit. Though the PPD p-value under the MCC models is still
away from 0.50. In our future research, we plan to explore covariates related to
compliance superclasses and time-varying compliance classes to improve the fit of
the MCC model.
In our current analysis we model the relationship between baseline depression
severity and compliance at 4 months, which indirectly models the relationship
between baseline depression and longitudinal compliance. It is of clinical interest
to identify patient characteristics that relate to treatment compliance. If clinicians can identify patients who are likely to comply to treatment over time and
those less likely to comply, then clinicians may be able to target patients with particular attributes and tailor treatment for different patients to optimize patient
treatment adherence and treatment outcomes. We are pursuing other predictors
of longitudinal compliance in our current work.
One limitation of our proposed method is that the principal effect does not provide
straightforward causal interpretation. Although the superclasses defined here provide convenient summaries of the longitudinal compliance patterns, they do not
represent specific compliance patterns. Therefore, the ITT contrasts stratified on
superclasses do not have straightforward causal interpretations.
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Appendix: Conditional draws of the Gibbs
sampler

Let Yi and Ci denote the vectors of Yij and Cij for subject i. For notational
simplicity, let Xij = [I(Ci1 = c, Zi = 0), · · · , I(Ci5 = n, Zi = 1), Ai ] denote the
row vector of the fixed effect, and Xi denote the design matrix of the fixed effect
for subject i with 5 (number of follow-ups) rows. Let β = [λ1c0 , · · · , λ5n1 , γ]
denote the vector of coefficients corresponding to the fixed effect.
The distributions from which parameters are drawn at each iteration in the Gibbs
sampling are as follows:
¡

¢
β|X, Y, W, ϕ, σ 2 , µβ , Σ−1
∼ M V N (µ̂, Σ̂)
β
P
−1
T
T
σ −2 N
i=1 Xi (Yi −Wi ϕi )+Σβ µβ
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−2
σ
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P
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−1
Σ̂ = (σ −2 i=1 XTi Xi + Σ−1
β )

³
´
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T
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´
¢
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(p1 , · · · , pK |U, a1 , · · · , ak ) ∼ Dirichlet(r1 , · · · , rK )
N
X
r1 =
I(Ui = 1) + a1
rK =

i=1
N
X

I(Ui = K) + aK

i=1

(πkjη0 c , πkjη0 n |C, bc , bn ) ∼ Dirichlet(sc , sn )
N
X
sc =
I(Ui = k, Ci,j−1 = η 0 , Cij = c) + bc
sn =

i=1
N
X

I(Ui = k, Ci,j−1 = η 0 , Cij = n) + bn

i=1

P (Ui = k|Ci , Qi , α, p1 , · · · , pk )
"
#" 5
#
Y
Y Y Y I(U =k,C
0
=η ,Cij =η)
∝ pk ×
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η

j=2 η 0

η
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and φ(S) is the pdf for standard normal distribution evaluated at S
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TABLES

Table 1: Posterior Means and 95% Credible Intervals (in parentheses) for the
Time- and Compliance Superclass-Varying Compliance Probabilities Assuming
the Average Baseline HAMD of 18.1 and Superclass Probabilities Under the CI
Model.
Low
Time
Compliers
4-months 0.43(0.33,0.53)
8-months 0.01(0.00,0.07)
12-months 0.01(0.00,0.04)
18-months 0.06(0.02,0.12)
24-months 0.04(0.01,0.09)
P (Ui )
0.28(0.23,0.33)

Decreasing
Compliers
0.99(0.96,1.00)
0.99(0.94,1.00)
0.51(0.36,0.66)
0.11(0.00,0.28)
0.01(0.00,0.07)
0.16(0.12,0.22)

High
Compliers
1.00(0.98,1.00)
1.00(0.99,1.00)
1.00(0.98,1.00)
0.99(0.98,1.00)
0.83(0.77,0.90)
0.56(0.50,0.62)
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TABLES

Table 2: Posterior Means and 95% Credible Intervals (in parentheses) for the ITT
Contrasts of the Outcome Within Compliance Superclasses Under the CI Model.
Low
Decreasing
High
Time
Compliers
Compliers
Compliers
4-months -7.54(-10.05,-2.00) -1.35(-3.23,0.10) -1.32(-3.20, 0.09)
8-months -3.39(- 7.24, 0.81) -0.93(-2.78,0.83) -0.92(-2.78, 0.86)
12-months 0.84(- 2.21, 3.95) -0.61(-2.11,1.05) -2.03(-3.86,-0.14)
18-months 1.44(- 1.40, 4.07) 1.28(-1.35,3.85) -1.34(-3.33, 0.64)
24-months 0.04(- 2.58, 2.69) 0.10(-2.61,2.85) -1.50(-3.72, 0.63)
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TABLES

Table 3: Posterior Means and 95% Credible Intervals (in parentheses) for the
Time- and Compliance Superclass-Varying Compliance Probabilities Assuming
the Average Baseline HAMD of 18.1 and Superclass Probabilities Under the MCC
Model.
Increasing
Time
Noncompliers
4-months 0.66(0.53,0.80)
8-months 0.38(0.20,0.56)
12-months 0.19(0.00,0.40)
18-months 0.10(0.02,0.31)
24-months 0.02(0.00,0.07)
P (Ui )
0.42(0.25,0.56)

Erratic
Compliers
0.38(0.00,1.00)
0.83(0.07,1.00)
0.32(0.00,1.00)
0.93(0.12,1.00)
0.66(0.00,1.00)
0.04(0.00.0.15)

High
Compliers
0.99(0.88,1.00)
0.98(0.86,1.00)
0.99(0.86,1.00)
0.96(0.76,1.00)
0.88(0.65,1.00)
0.54(0.42,0.72)
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TABLES

Table 4: Posterior Means and 95% Credible Intervals (in parentheses) of the
Transitional Probabilities Under the MCC model.
Superclass
j P (Ci,j = c|Ci,j−1 = c, Ui )
Increasing
2
0.57(0.34,0.77)
Noncomplier 3
0.45(0.00,0.77)
4
0.27(0.00,1.00)
5
0.10(0.00,0.51)
2
0.67(0.00,1.00)
Erratic
Complier
3
0.31(0.00,1.00)
4
0.64(0.00,1.00)
5
0.68(0.00,1.00)
High
2
1.00(0.99,1.00)
Complier
3
1.00(1.00,1.00)
4
0.97(0.84,1.00)
5
0.91(0.76,1.00)

P (Ci,j = c|Ci,j−1 = n, Ui )
0.01(0.00,0.06)
0.01(0.00,0.03)
0.06(0.02,0.12)
0.02(0.00,0.05)
0.56(0.00,1.00)
0.48(0.00,1.00)
0.78(0.00,1.00)
0.54(0.00,1.00)
0.15(0.00,1.00)
0.44(0.00,1.00)
0.54(0.00,1.00)
0.46(0.00,1.00)
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TABLES

Table 5: Posterior Means and 95% Credible Intervals (in parentheses) for the
ITT Contrasts of the Outcome Within Compliance Superclasses Under the MCC
model.
Increasing
Time
Noncompliers
4-months -5.19(-7.33,-3.04)
8-months -2.70(-5.21,-0.34)
12-months 0.52(-1.92, 3.13)
18-months 1.55(-1.05, 4.23)
24-months 0.48(-2.12, 2.95)

Erratic
Compliers
-8.32(-15.33,-0.76)
-1.39(- 4.71, 0.58)
-0.01(- 3.41, 3.75)
-1.28(- 3.29, 1.48)
-1.31(- 4.57, 2.35)

High
Compliers
-1.46(-3.05,-0.04)
-0.89(-2.57, 0.77)
-2.10(-3.81,-0.37)
-1.38(-3.23, 0.50)
-2.02(-4.53, 0.11)
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